Stocks Health care MGNX
NASDAQ · Health careMacrogenics Inc (MGNX)
Macrogenics Inc brought in $183M of revenue over the twelve months to June 30, 2026, up 21.9% from a year earlier. It posted a net loss of $14.6M. In fiscal 2025 capital spending exceeded operating cash flow by $83M. At June 30, 2026 it held $113.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Macrogenics Inc
- Net worth
- Macrogenics Inc has a market value (market cap) of $154.2M at the latest share price, and shareholders' equity of $42.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $149.5M (-0.3% year on year), with a net loss of $74.6M. Over the 12 months to June 30, 2026: revenue $183M, net loss $14.6M.
- Cash flow
- In fiscal 2025 operations used $81M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Macrogenics Inc's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Macrogenics Inc does
Macrogenics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MGNX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $149.5M | -$74.6M | -$1.18 | -$83M |
| 2024 | $150M | -$67M | -$1.07 | -$72.1M |
| 2023 | $58.7M | -$9.1M | -$0.15 | -$80M |
| 2022 | $151.9M | -$119.8M | -$1.95 | -$90.6M |
| 2021 | $77.4M | -$202.1M | -$3.37 | -$150M |
| 2020 | $104.9M | -$129.7M | -$2.47 | -$117.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MGNX ranks in Health care
Latest SEC filings
What Macrogenics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- October 23, 2026Other event 8-K
- September 3, 2026
- September 3, 2026Exhibits 8-K/A
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 378% to $32.8M versus the same quarter last year; diluted EPS $0.31 versus -$0.57.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 3, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 23, 2026Other event 8-K
Insider trades
What the people running Macrogenics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $129.1K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Bonvini EzioSr VP, Research & CSO | Exercised options | 8,000 | $20.8K |
| August 19, 2026 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Soldpre-planned (10b5-1) | 31,105 | $129.1K |
| August 17, 2026 | Bonvini EzioSr VP, Research & CSO | Exercised options | 40,000 | $104K |
| May 18, 2026 | O'Brien Federica F.Director | Exercised options | 3,750 | - |
| May 18, 2026 | Stump David CDirector | Exercised options | 3,750 | - |
| May 18, 2026 | Hurwitz EdwardDirector | Exercised options | 3,750 | - |
| May 18, 2026 | Heiden William KDirector | Exercised options | 3,750 | - |
| May 18, 2026 | Liu MargaretDirector | Exercised options | 3,750 | - |
Who owns MGNX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 7.88% | August 14, 2026 |
| James N. Topper13G, passive with 16 related filers | 5.1% | November 20, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 122 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Armistice Capital, LLC | 5,006,752 | -1,005,248 |
| BlackRock, Inc. | 4,679,229 | +3,516,083 |
| Vanguard Capital Management LLC | 2,656,010 | +2,157 |
| Renaissance Technologies LLC | 2,632,750 | -330,809 |
| Bank of America Corp | 2,488,252 | +86,438 |
| Two Sigma Investments, LP | 2,465,699 | -62,130 |
| Millennium Management LLC | 2,374,296 | -420,061 |
| Wasatch Advisors LP | 2,018,881 | +459,180 |
| RA Capital Management, L.P. | 1,864,176 | 0 |
| Vanguard Portfolio Management LLC | 1,820,231 | +611,456 |
| Mackenzie Financial Corp | 1,642,626 | +1,045,184 |
| Marshall Wace, Llp | 1,616,220 | -409,306 |
| Geode Capital Management, LLC | 1,576,549 | +879,228 |
| Affinity Asset Advisors, LLC | 1,216,606 | +716,606 |
| D. E. Shaw & Co., Inc. | 1,062,991 | +4,567 |
| Jacobs Levy Equity Management, Inc | 1,002,274 | +561,131 |
| Connor, Clark & Lunn Investment Management Ltd. | 1,000,412 | +133,163 |
| State Street Corp | 863,663 | +569,976 |
| Goldman Sachs Group Inc | 558,001 | +284,523 |
| Northern Trust Corp | 516,129 | +363,847 |
Insiders
15 insiders reported holding 1,661,393 shares in total, about $4M at the last price.
| Holder | Shares |
|---|---|
| Koenig ScottDirector | 867,240 |
| Karrels JamesSVP and CFO | 206,037 |
| Bonvini EzioSr VP, Research & CSO | 193,799 |
| Heiden William KDirector | 114,750 |
| Risser Eric BlasiusPresident and CEO, Director | 77,169 |
| Hurwitz EdwardDirector | 47,824 |
| Spitznagel ThomasSr VP, Technical Ops | 38,543 |
| O'Brien Federica F.Director | 14,750 |
| Stump David CDirector | 14,750 |
| Liu MargaretDirector | 14,750 |
Questions about MGNX
What does Macrogenics Inc do?
Macrogenics Inc is a company in the Health care sector, listed on NASDAQ as MGNX. Its shares trade on NASDAQ under the ticker MGNX.
What is Macrogenics Inc's net worth?
Macrogenics Inc has a market value (market cap) of $154.2M at the latest share price, and shareholders' equity of $42.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Macrogenics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.6M on revenue of $183M.
How much revenue does Macrogenics Inc make?
Over the twelve months to June 30, 2026 Macrogenics Inc reported revenue of $183M. That is 21.9% more than a year earlier.
When did Macrogenics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from November 3, 2026.
When is Macrogenics Inc's next earnings report?
Macrogenics Inc's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MGNX with
Follow MGNX
Get an email when Macrogenics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Macrogenics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.